Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOVNYSE:GKOSNYSE:INSPNYSE:STVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$31.36-1.3%$33.05$28.83▼$49.83$1.82B1.72880,562 shs983,181 shsGKOSGlaukos$103.42+2.0%$95.06$77.10▼$163.71$5.80B0.8735,543 shs982,839 shsINSPInspire Medical Systems$129.28-2.4%$143.59$123.00▼$225.00$3.83B1.29548,047 shs722,583 shsSTVNStevanato Group€24.51-0.5%€23.08€17.12▼€25.88€7.42B0.53340,247 shs237,000 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis-1.32%+4.51%+0.13%-15.49%-30.62%GKOSGlaukos+1.92%+6.84%+9.64%+6.45%-12.62%INSPInspire Medical Systems-2.39%-0.46%-6.35%-18.04%-3.40%STVNStevanato Group-0.61%+3.77%+11.16%+17.16%+33.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENOVEnovis3.2116 of 5 stars3.43.00.00.01.81.71.9GKOSGlaukos4.4035 of 5 stars4.41.00.04.42.61.70.6INSPInspire Medical Systems4.8076 of 5 stars4.41.00.04.82.92.51.9STVNStevanato GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.80Moderate Buy$58.0084.95% UpsideGKOSGlaukos 2.75Moderate Buy$134.6730.21% UpsideINSPInspire Medical Systems 2.73Moderate Buy$211.9163.91% UpsideSTVNStevanato Group 2.86Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ENOV, STVN, GKOS, and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025STVNStevanato GroupWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/6/2025INSPInspire Medical SystemsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$220.00 ➝ $200.005/6/2025INSPInspire Medical SystemsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$235.00 ➝ $195.005/6/2025INSPInspire Medical SystemsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$195.00 ➝ $174.005/6/2025INSPInspire Medical SystemsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$230.00 ➝ $236.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.11B0.85$19.01 per share1.65$45.10 per share0.70GKOSGlaukos$383.48M15.41N/AN/A$13.91 per share7.43INSPInspire Medical Systems$840.11M4.54$1.67 per share77.50$23.01 per share5.62STVNStevanato Group€1.19B6.21€0.75 per share32.64€5.02 per share4.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$825.49M-$13.95N/A9.83N/A-37.65%5.99%3.44%8/6/2025 (Estimated)GKOSGlaukos-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)INSPInspire Medical Systems$53.51M$2.1759.5840.152.037.92%10.00%8.68%8/5/2025 (Estimated)STVNStevanato Group€127.45M€0.5148.0642.262.3511.14%10.00%6.03%N/ALatest ENOV, STVN, GKOS, and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/AINSPInspire Medical SystemsN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsLatest ENOV, STVN, GKOS, and INSP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.522.551.32GKOSGlaukos0.096.495.62INSPInspire Medical SystemsN/A9.017.44STVNStevanato Group0.221.831.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%GKOSGlaukos99.04%INSPInspire Medical Systems94.91%STVNStevanato GroupN/AInsider OwnershipCompanyInsider OwnershipENOVEnovis2.70%GKOSGlaukos6.40%INSPInspire Medical Systems4.10%STVNStevanato GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis7,36757.12 million55.58 millionOptionableGKOSGlaukos78057.14 million53.48 millionOptionableINSPInspire Medical Systems1,24629.49 million28.82 millionOptionableSTVNStevanato Group5,521302.84 millionN/AOptionableENOV, STVN, GKOS, and INSP HeadlinesRecent News About These CompaniesStevanato Group (NYSE:STVN) Receives "Outperform" Rating from William BlairJuly 1 at 2:35 AM | americanbankingnews.comStevanato Group S.p.A. (NYSE:STVN) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 1 at 2:22 AM | marketbeat.comWilliam Blair Reaffirms Outperform Rating for Stevanato Group (NYSE:STVN)June 30 at 2:09 PM | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Shares Bought by Peregrine Capital Management LLCJune 30 at 8:33 AM | marketbeat.comSTVN Stevanato Group S.p.A. - Seeking AlphaJune 29 at 8:59 AM | seekingalpha.comStevanato Group (NYSE:STVN) Sets New 1-Year High - What's Next?June 26, 2025 | marketbeat.comStevanato Group S.P.A. (IT0005452658.SG)June 26, 2025 | sg.finance.yahoo.comCooper Investors PTY Ltd. Buys 25,221 Shares of Stevanato Group S.p.A. (NYSE:STVN)June 24, 2025 | marketbeat.comStevanato: Recovery Underway, Buy ConfirmedJune 22, 2025 | seekingalpha.comStevanato Group S.p.A. (NYSE:STVN) Shares Sold by Riverbridge Partners LLCJune 20, 2025 | marketbeat.comUSNA vs. STVN: Which Stock Is the Better Value Option?June 18, 2025 | zacks.comConestoga Capital Advisors LLC Raises Position in Stevanato Group S.p.A. (NYSE:STVN)June 17, 2025 | marketbeat.comStevanato Group (NYSE:STVN) Shares Down 4.7% - Here's What HappenedJune 12, 2025 | marketbeat.comSubcontractor sues for nearly $1.6M in unpaid work on Stevanato site in FishersJune 12, 2025 | theindianalawyer.comTYarbrough Capital LLC Acquires Shares of 16,113 Stevanato Group S.p.A. (NYSE:STVN)June 8, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 6, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Short Interest UpdateJune 5, 2025 | marketbeat.comEx-Dividend Reminder: Stevanato Group SpA, Golden Ocean Group and Flowers FoodsJune 4, 2025 | nasdaq.comWellington Management Group LLP Trims Position in Stevanato Group S.p.A. (NYSE:STVN)June 4, 2025 | marketbeat.comGRFS vs. STVN: Which Stock Is the Better Value Option?June 2, 2025 | zacks.comStevanato Group S.p.A. (STVN): A Bull Case TheoryMay 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENOV, STVN, GKOS, and INSP Company DescriptionsEnovis NYSE:ENOV$31.36 -0.42 (-1.32%) Closing price 06/30/2025 03:58 PM EasternExtended Trading$31.70 +0.34 (+1.08%) As of 08:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Glaukos NYSE:GKOS$103.42 +2.00 (+1.97%) Closing price 06/30/2025 03:58 PM EasternExtended Trading$103.30 -0.12 (-0.12%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inspire Medical Systems NYSE:INSP$129.28 -3.13 (-2.36%) Closing price 06/30/2025 03:58 PM EasternExtended Trading$130.07 +0.79 (+0.61%) As of 09:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Stevanato Group NYSE:STVN€24.51 -0.13 (-0.53%) As of 06/30/2025 03:58 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Why McCormick Stock Could Soar After Durables Data Surprise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
